{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:13:07Z","timestamp":1790712787863,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":296,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81402444"],"award-info":[{"award-number":["81402444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["24NSFSC2149"],"award-info":[{"award-number":["24NSFSC2149"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinsp.2025.100809","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:30:45Z","timestamp":1761931845000},"page":"100809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Epiregulin drives keratinocyte hyperproliferation in sorafenib-induced hand-foot skin reaction: A mechanistic and therapeutic insight"],"prefix":"10.1016","volume":"80","author":[{"given":"Yuxin","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8025-998X","authenticated-orcid":false,"given":"Xiao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6273-8411","authenticated-orcid":false,"given":"Xiaorong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7185-8251","authenticated-orcid":false,"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0790-1621","authenticated-orcid":false,"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3528-4877","authenticated-orcid":false,"given":"Jingbin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6570-9432","authenticated-orcid":false,"given":"Zhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5467-6210","authenticated-orcid":false,"given":"Jianlin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8856-0445","authenticated-orcid":false,"given":"Guojun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5740-7715","authenticated-orcid":false,"given":"Zhengwei","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clinsp.2025.100809_bib0001","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/17512433.2019.1689122","article-title":"Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management","volume":"12","author":"Ai","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100809_bib0002","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinsp.2025.100809_bib0003","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/EDBK_237555","article-title":"Evolving landscape of systemic therapy for hepatocellular carcinoma: breakthroughs, toxicities, and future frontiers","volume":"39","author":"Grieb","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100809_bib0004","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clinsp.2025.100809_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.clinsp.2025.100809_bib0006","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100809_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120877","article-title":"A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting","volume":"10","author":"Fishman","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.clinsp.2025.100809_bib0008","first-page":"652","article-title":"The hand-foot-syndrome associated with medical tumor therapy - classification and management","volume":"8","author":"Degen","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.clinsp.2025.100809_bib0009","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/14737140.2014.894465","article-title":"Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis","volume":"14","author":"Abdel-Rahman","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.clinsp.2025.100809_bib0010","first-page":"1827","article-title":"Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature","volume":"23","author":"Massey","year":"2015","journal-title":"Support Care Cancer"},{"issue":"38","key":"10.1016\/j.clinsp.2025.100809_bib0011","doi-asserted-by":"crossref","first-page":"13921","DOI":"10.1073\/pnas.0404217101","article-title":"Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage","volume":"101","author":"Shirasawa","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.clinsp.2025.100809_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312828","article-title":"The role of EREG\/EGFR pathway in tumor progression","volume":"22","author":"Cheng","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.clinsp.2025.100809_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12881","article-title":"Epiregulin promotes hair growth via EGFR-medicated epidermal and ErbB4-mediated dermal stimulation","volume":"53","author":"Choi","year":"2020","journal-title":"Cell Prolif"},{"issue":"10","key":"10.1016\/j.clinsp.2025.100809_bib0014","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1634\/theoncologist.12-10-1178","article-title":"Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib","volume":"12","author":"Beldner","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clinsp.2025.100809_bib0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.biopha.2017.03.090","article-title":"Treatment with adipose derived mesenchymal stem cells and their conditioned media reverse carrageenan induced paw oedema in db\/db mice","volume":"90","author":"Shree","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100809_bib0016","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinsp.2025.100809_bib0017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2020.09.012","article-title":"Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: a multicenter, randomised, double-blind controlled study","volume":"140","author":"Lee","year":"2020","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clinsp.2025.100809_bib0018","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/jid.2012.42","article-title":"Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression","volume":"132","author":"Grether-Beck","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.clinsp.2025.100809_bib0019","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s13555-021-00611-y","article-title":"Urea in dermatology: a review of its emollient, moisturizing, keratolytic, skin barrier enhancing and antimicrobial properties","volume":"11","author":"Piquero-Casals","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100809_bib0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.clinsp.2025.100809_bib0021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100809_bib0022","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00280-013-2116-y","article-title":"Physiologically based pharmacokinetic models for everolimus and sorafenib in mice","volume":"71","author":"Pawaskar","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.clinsp.2025.100809_bib0023","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/1346-8138.16003","article-title":"Possible role of epiregulin from dermal fibroblasts in the keratinocyte hyperproliferation of psoriasis","volume":"48","author":"Iwata","year":"2021","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100809_bib0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdermsci.2006.08.010","article-title":"Epiregulin, a member of the EGF family, is over-expressed in psoriatic epidermis","volume":"45","author":"Shirakata","year":"2007","journal-title":"J Dermatol Sci"},{"issue":"8","key":"10.1016\/j.clinsp.2025.100809_bib0025","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1074\/jbc.275.8.5748","article-title":"Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes","volume":"275","author":"Shirakata","year":"2000","journal-title":"J Biol Chem"},{"issue":"22","key":"10.1016\/j.clinsp.2025.100809_bib0026","doi-asserted-by":"crossref","first-page":"10591","DOI":"10.1111\/jcmm.16990","article-title":"ERK5 signalling pathway is a novel target of sorafenib: implication in EGF biology","volume":"25","author":"Ortega-Muelas","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100809_bib0027","first-page":"5620","article-title":"Sorafenib inhibited cell growth through the MEK\/ERK signaling pathway in acute promyelocytic leukemia cells","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clinsp.2025.100809_bib0028","first-page":"91","article-title":"Epiregulin as a therapeutic target in non-small-cell lung cancer","volume":"6","author":"Sunaga","year":"2015","journal-title":"Lung Cancer (Auckl)"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100809_bib0029","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1172\/JCI63748","article-title":"Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK","volume":"123","author":"Neufert","year":"2013","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.clinsp.2025.100809_bib0030","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-020-0309-6","article-title":"s-HBEGF\/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide","volume":"30","author":"Luo","year":"2020","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100809_bib0031","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1592\/phco.30.1.52","article-title":"Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction","volume":"30","author":"Jain","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinsp.2025.100809_bib0032","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, pdgfr\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100809_bib0033","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinsp.2025.100809_bib0034","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2017.12.014","article-title":"A vascular endothelial growth factor-dependent sprouting angiogenesis assay based on an In vitro Human blood vessel model for the study of anti-angiogenic drugs","volume":"27","author":"Pauty","year":"2018","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100809_bib0035","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1158\/0008-5472.CAN-24-0798","article-title":"Antibody-drug conjugates targeting the EGFR ligand epiregulin elicit robust antitumor activity in colorectal cancer","volume":"85","author":"Jacob","year":"2025","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100809_bib0036","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.2013.753","article-title":"Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer","volume":"110","author":"Jonker","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100809_bib0037","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1179\/1973947814Y.0000000189","article-title":"Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials","volume":"27","author":"Qi","year":"2015","journal-title":"J Chemother"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225002273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225002273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:46:49Z","timestamp":1790711209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593225002273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"alternative-id":["S1807593225002273"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100809","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epiregulin drives keratinocyte hyperproliferation in sorafenib-induced hand-foot skin reaction: A mechanistic and therapeutic insight","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100809"}}